Pan-cancer analysis identified OAS1 as a potential prognostic biomarker for multiple tumor types

Jiang, Shan; Deng, Xinzhou; Luo, Ming; Zhou, Le; Chai, Jingjing; Tian, Chao; Yan, Yutao; Luo, Zhiguo

doi:10.3389/fonc.2023.1207081

Cited by 3 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The opposite effect was obtained when RNase L expression was restored [ 90 ]. Furthermore, in pancancer studies, OAS1 was reported to be highly expressed in a wide range of tumors [ 91 ]. The cytokines IFN-λ1, CXCL10, and IL-6 contribute to antiproliferative phenotypes [ 92 – 94 ].…”

Section: Vault Rnas and Innate Immunitymentioning

confidence: 99%

Crosstalk between vault RNAs and innate immunity

Avila-Bonilla,

Martínez-Montero

2024

Mol Biol Rep

View full text Add to dashboard Cite

Purpose Vault (vt) RNAs are noncoding (nc) RNAs transcribed by RNA polymerase III (RNA Pol III) with 5ʹ-triphosphate (5ʹ-PPP) termini that play significant roles and are recognized by innate immune sensors, including retinoic acid-inducible protein 1 (RIG-I). In addition, vtRNAs adopt secondary structures that can be targets of interferon-inducible protein kinase R (PKR) and the oligoadenylate synthetase (OAS)/RNase L system, both of which are important for activating antiviral defenses. However, changes in the expression of vtRNAs have been associated with pathological processes that activate proinflammatory pathways, which influence cellular events such as differentiation, aging, autophagy, apoptosis, and drug resistance in cancer cells. Results In this review, we summarized the biology of vtRNAs and focused on their interactions with the innate immune system. These findings provide insights into the diverse roles of vtRNAs and their correlation with various cellular processes to improve our understanding of their biological functions.

show abstract

Section: Vault Rnas and Innate Immunitymentioning

confidence: 99%

Crosstalk between vault RNAs and innate immunity

Avila-Bonilla,

Martínez-Montero

2024

Mol Biol Rep

View full text Add to dashboard Cite

show abstract

“…The HCCS target siRNA was transfected with riboFECTTMCP transfection reagent (ribobio, Guangzhou, China). The siRNA sequences of HCCS as follow: negative control (NC) (5'-TTCTCCGAGCGTCACGT-3') [22], siRNA-HCCS #1 (5'-GGAUGCCCGAUGCAUGAAGTT-3'), siRNA-HCCS #2 (5'-CACCAAAUCAAACACCAGCTT-3'), and siRNA-HCCS #3 (5'-AUAACGAGC AGGCUUGGAATT − 3').…”

Section: Cell Culture and Transfectionmentioning

confidence: 99%

Section: Cell Culture and Transfectionmentioning

confidence: 99%

Pan-Cancer Analysis of the Prognostic and Immunological Role of HCCS: A Potential Target for Survival and Immunotherapy

Luo,

Deng,

Jiang

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Holocytochrome c synthase (HCCS) is a cytochrome c synthase that connects heme to cytochrome c. At present, the role of HCCS in tumors have not been reported. Methods: The TIMER2, UALCAN, and HPA databases were also used to explore the expression level of HCCS, the GEPIA2 database was utilized to investigate the relationship between HCCS and the prognosis of patients with tumor, and the TISIDB website was utilized to study the relationship between HCCS and molecular subtypes and immune subtypes. R 3.6.2 software was used to construct ROC curves, DAVID database was used to perform GO and KEGG annotations. Results: We find that HCCS is differentially expressed in 8 types of tumors, high expression of HCCS was correlated with poor prognosis in 5 types of tumors and good prognosis in 3 types of tumors. HCCS is differentially expressed in various molecular subtypes of 14 tumors and various immune subtypes of 19 tumors. HCCS has potential value for the diagnosis estimation of 12 types of tumors. HCCS may be involved in multiple processes, such as organelle fission, chromosome segregation and cell cycle. Silencing HCCS significantly inhibits LAUD cell proliferation, promotes G2M cell cycle arrest, and cisplatin induced cell apoptosis. HCCS is associated with the expression of PD-L1 and immunotherapeutic efficacy in several tumors. Conclusions: This study suggests that HCCS is a biomarker for the diagnosis and prognosis estimation of various tumors, and it may also affect the efficacy of immunotherapy for tumors.

show abstract

Genome-wide analysis reveals the MORC3-mediated repression of PD-L1 expression in head and neck cancer

Fu,

Chang,

et al. 2024

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

IntroductionProgrammed death-ligand 1 (PD-L1) plays essential roles in the negative regulation of anti-tumor immunity. However, the regulatory mechanisms of PD-L1 expression need further exploration. MORC family CW-type zinc finger 3 (MORC3) is a transcriptional factor that regulates innate immune responses, but the expression and roles of MORC3 in cancers remain largely unknown. The present study explored the expression of MORC3 in cancers at both transcriptional and translational levels.MethodsThe target genes and pathways were analyzed using RNA interference (RNAi), RNA sequencing (RNA-seq), and quantitative real-time polymerase chain reaction (qRT-PCR) technology in head and neck cancer cells. The expression of MORC3 and its target genes were also analyzed in single cancer cells.ResultsMORC3 was significantly downregulated in multiple cancers, including head and neck cancer, and low expression of MORC3 was associated with poor overall survival. MORC3 knockdown significantly increased the expression of many immune-related genes, including interferon (IFN)-associated genes [MX dynamin like GTPase 2 (MX2), interferon induced protein with tetratricopeptide repeats 1 (IFIT1), interferon induced protein with tetratricopeptide repeats 2 (IFIT2), interferon regulatory factor 7 (IRF7), interferon regulatory factor 9 (IRF9), interferon induced protein 44 like (IFI44L), interferon induced transmembrane protein 1 (IFITM1), interferon induced transmembrane protein 3 (IFITM3), interferon induced protein 44 (IFI44), and interferon induced with helicase C domain 1 (IFIH1)]. MORC3 knockdown significantly upregulated PD-L1 and signal transducer and activator of transcription 1 (STAT1) expression. Moreover, the LINC00880 immune-related long non-coding RNA (lnc-RNA) was upregulated by MORC3 knockdown. Silencing LINC00880 attenuated PD-L1 expression. MORC3 knockdown also increased the expression of cellular proliferation-related genes and promoted cancer cell proliferation.ConclusionThe present study demonstrated that MORC3 regulates IFN-associated pathways and is a novel repressor of PD-L1 expression and cancer cell proliferation.

show abstract

Pan-cancer analysis identified OAS1 as a potential prognostic biomarker for multiple tumor types

Cited by 3 publications

References 39 publications

Crosstalk between vault RNAs and innate immunity

Crosstalk between vault RNAs and innate immunity

Pan-Cancer Analysis of the Prognostic and Immunological Role of HCCS: A Potential Target for Survival and Immunotherapy

Genome-wide analysis reveals the MORC3-mediated repression of PD-L1 expression in head and neck cancer

Contact Info

Product

Resources

About